Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell...

Full description

Saved in:
Bibliographic Details
Main Authors: John M. Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D. Zelenetz, Roch Houot, Sattva S. Neelapu, Theodore F. Logan, Izidore S. Lossos, Walter J. Urba, Gilles Salles, Radhakrishnan Ramchandren, Caron A. Jacobson, John E. Godwin, Cecilia Carpio, Deanne Lathers, Yali Liu, Jaclyn Neely, Satyendra Suryawanshi, Yoshinobu Koguchi, Ronald Levy
Format: Artigo
Language:English
Published: 2020
Online Access:https://doi.org/10.1002/ajh.25757
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25757
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ajh.25757
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25757

Similar Items